Opportunities for improving cancer treatment using systems biology.

Current cancer therapies target a limited set of tumor features, rather than considering the tumor as a whole. Systems biology aims to reveal therapeutic targets associated with a variety of facets in an individual's tumor, such as genetic heterogeneity and its evolution, cancer cell-autonomous phenotypes, and microenvironmental signaling. These disparate characteristics can be reconciled using mathematical modeling that incorporates concepts from ecology and evolution. This provides an opportunity to predict tumor growth and response to therapy, to tailor patient-specific approaches in real time or even prospectively. Importantly, as data regarding patient tumors is often available from only limited time points during treatment, systems-based approaches can address this limitation by interpolating longitudinal events within a principled framework. This review outlines areas in medicine that could benefit from systems biology approaches to deconvolve the complexity of cancer.

[1]  Éva E Plagányi,et al.  Future recovery of baleen whales is imperiled by climate change , 2019, Global change biology.

[2]  Jeong Eon Lee,et al.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer , 2017, Nature Communications.

[3]  P. Fortina,et al.  The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.

[4]  Hua Chen,et al.  Targeting protein kinases to reverse multidrug resistance in sarcoma. , 2016, Cancer treatment reviews.

[5]  Mark W Schwartz,et al.  A resource ratio theory of cooperation. , 2010, Ecology letters.

[6]  I. Ionita-Laza,et al.  Estimating the number of unseen variants in the human genome , 2009, Proceedings of the National Academy of Sciences.

[7]  A. Suresh,et al.  Optimal prediction of the number of unseen species , 2016, Proceedings of the National Academy of Sciences.

[8]  Shaker A. Mousa,et al.  The Role of Angiogenesis in Cancer Treatment , 2017, Biomedicines.

[9]  S. Sager,et al.  Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function. , 2011, Mathematical biosciences.

[10]  H. Shimizu,et al.  Prediction of Cross-resistance and Collateral Sensitivity by Gene Expression profiles and Genomic Mutations , 2017, Scientific Reports.

[11]  J. Gómez,et al.  Are Mixed-Species Bird Flocks Stable through Two Decades? , 2013, The American Naturalist.

[12]  Stephen P Ellner,et al.  Does rapid evolution matter? Measuring the rate of contemporary evolution and its impacts on ecological dynamics. , 2011, Ecology letters.

[13]  S. Rajappa,et al.  Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment , 2019, Advances in Therapy.

[14]  L. Norton,et al.  The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens , 2006, Nature Clinical Practice Oncology.

[15]  Eytan Ruppin,et al.  Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.

[16]  Lei Zheng,et al.  HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Francisco Azuaje,et al.  Computational models for predicting drug responses in cancer research , 2016, Briefings Bioinform..

[18]  Clotilde Théry,et al.  Communication by Extracellular Vesicles: Where We Are and Where We Need to Go , 2016, Cell.

[19]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[20]  Jianhua Xing,et al.  Coupled reversible and irreversible bistable switches underlying TGFβ-induced epithelial to mesenchymal transition. , 2013, Biophysical journal.

[21]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[22]  Giles Hooker,et al.  Parameterizing state–space models for infectious disease dynamics by generalized profiling: measles in Ontario , 2011, Journal of The Royal Society Interface.

[23]  Robert K. Colwell,et al.  Estimating terrestrial biodiversity through extrapolation. , 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[24]  Yvan Saeys,et al.  A comparison of single-cell trajectory inference methods , 2019, Nature Biotechnology.

[25]  J. Wietrzyk,et al.  Antiangiogenic cancer treatment: The great discovery and greater complexity (Review) , 2016, International journal of oncology.

[26]  Amir Abdollahi,et al.  Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  Jonathan M. Levine,et al.  Effects of rapid evolution on species coexistence , 2019, Proceedings of the National Academy of Sciences.

[28]  I. Fidler,et al.  The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organs , 2011, International journal of cancer.

[29]  Giuseppe Curigliano,et al.  Targeting the microenvironment in solid tumors. , 2018, Cancer treatment reviews.

[30]  G. Demetri,et al.  Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. , 1989, Blood.

[31]  Evan A. Clayton,et al.  Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy , 2018, Scientific Reports.

[32]  Madhav V. Marathe,et al.  Systems Modeling of Molecular Mechanisms Controlling Cytokine-driven CD4+ T Cell Differentiation and Phenotype Plasticity , 2013, PLoS Comput. Biol..

[33]  Lucy Ireland,et al.  Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance , 2018, Front. Cell Dev. Biol..

[34]  Robert A. Gatenby,et al.  Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy , 2019, Clinical Cancer Research.

[35]  Paolo Vineis,et al.  Deciphering the complex: Methodological overview of statistical models to derive OMICS‐based biomarkers , 2013, Environmental and molecular mutagenesis.

[36]  K. Polyak,et al.  Tumorigenesis: it takes a village , 2015, Nature Reviews Cancer.

[37]  William S. Hlavacek,et al.  Prediction of Optimal Drug Schedules for Controlling Autophagy , 2018, Scientific Reports.

[38]  Heyrim Cho,et al.  Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy , 2017, Bulletin of Mathematical Biology.

[39]  Justin M. Wozniak,et al.  High-throughput cancer hypothesis testing with an integrated PhysiCell-EMEWS workflow , 2017, BMC Bioinformatics.

[40]  Sayan Mukherjee,et al.  A unifying framework for interpreting and predicting mutualistic systems , 2019, Nature Communications.

[41]  Shuigeng Zhou,et al.  Single-cell trajectories reconstruction, exploration and mapping of omics data with STREAM , 2019, Nature Communications.

[42]  Lin Zhou,et al.  Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma , 2017, Cancer medicine.

[43]  Yi Qin,et al.  The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer , 2018, Theranostics.

[44]  Robert A Gatenby,et al.  Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.

[45]  Brent S. Pedersen,et al.  Combating subclonal evolution of resistant cancer phenotypes , 2017, Nature Communications.

[46]  Joel s. Brown,et al.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.

[47]  Carsten Denkert,et al.  The landscape of metastatic progression patterns across major human cancers , 2014, Oncotarget.

[48]  Herschel Rabitz,et al.  Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability , 2018, Nature Communications.

[49]  M. Piccart-Gebhart,et al.  Mammaprint™: a comprehensive review. , 2019, Future oncology.

[50]  E. Song,et al.  Turning foes to friends: targeting cancer-associated fibroblasts , 2018, Nature Reviews Drug Discovery.

[51]  P. R. Atsatt,et al.  Plant Defense Guilds , 1976, Science.

[52]  Shan Jiang,et al.  Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. , 2019, Cell reports.

[53]  L. R. Benjamin,et al.  The theory and application of plant competition models: an agronomic perspective. , 2003, Annals of Botany.

[54]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 3.2018. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[55]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[56]  Kazuyuki Aihara,et al.  Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling , 2018, Scientific Reports.

[57]  Robert Tibshirani,et al.  DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity , 2018, Proceedings of the National Academy of Sciences.

[58]  Jean Clairambault,et al.  Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations , 2016, Biology Direct.

[59]  Ralph Weissleder,et al.  Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.

[60]  E. Leigh The evolution of mutualism , 2010, Journal of evolutionary biology.

[61]  Nasser K. Altorki,et al.  The lung microenvironment: an important regulator of tumour growth and metastasis , 2018, Nature Reviews Cancer.

[62]  Brett J Furnas,et al.  Detecting diversity: emerging methods to estimate species diversity. , 2014, Trends in ecology & evolution.

[63]  Nicola Miller,et al.  The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre , 2014, European journal of cancer.

[64]  J. Hughes,et al.  Counting the Uncountable: Statistical Approaches to Estimating Microbial Diversity , 2001, Applied and Environmental Microbiology.

[65]  Rodrigo Ramos-Jiliberto,et al.  A conceptual framework for studying the strength of plant-animal mutualistic interactions. , 2015, Ecology letters.

[66]  Mollie E. Brooks,et al.  Generalized linear mixed models: a practical guide for ecology and evolution. , 2009, Trends in ecology & evolution.

[67]  K. Pienta,et al.  Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.

[68]  Takehiko Yamanaka,et al.  Optimal management strategy of insecticide resistance under various insect life histories: Heterogeneous timing of selection and interpatch dispersal , 2017, Evolutionary applications.

[69]  S. Caja,et al.  Exosome-Based Cell-Cell Communication in the Tumor Microenvironment , 2018, Front. Cell Dev. Biol..

[70]  Atsushi Kawabata,et al.  Combining microvolume isotope analysis and numerical simulation to reproduce fish migration history , 2018, Methods in Ecology and Evolution.

[71]  Krister Wennerberg,et al.  Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression , 2017, Bioinform..

[72]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[73]  P. Sean Walsh,et al.  Analytical performance of a bronchial genomic classifier , 2016, BMC Cancer.

[74]  Tyvette S. Hilliard The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment , 2018, Cancers.

[75]  Yi Yin,et al.  Automatic classification of cervical cancer from cytological images by using convolutional neural network , 2018, Bioscience reports.

[76]  H. Cho,et al.  Modelling acute myeloid leukaemia in a continuum of differentiation states , 2018, Letters in biomathematics.

[77]  Varun Rastogi,et al.  Tumour Angiogenesis and Angiogenic Inhibitors: A Review. , 2015, Journal of clinical and diagnostic research : JCDR.

[78]  D. Welch,et al.  Defining the Hallmarks of Metastasis. , 2019, Cancer research.

[79]  Bonnie Berger,et al.  Generalizable and Scalable Visualization of Single-Cell Data Using Neural Networks. , 2018, Cell systems.

[80]  Regina S Baucom,et al.  Evolutionary and ecological insights from herbicide-resistant weeds: what have we learned about plant adaptation, and what is left to uncover? , 2019, The New phytologist.

[81]  M. L. Martins,et al.  A multiscale model for plant invasion through allelopathic suppression , 2010, Biological Invasions.

[82]  N. Maishi,et al.  Tumor endothelial cells accelerate tumor metastasis , 2017, Cancer science.

[83]  Lenwood S. Heath,et al.  DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data , 2017, bioRxiv.

[84]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[85]  Richard O Hynes,et al.  The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. , 2012, Cancer discovery.

[86]  Jun Li,et al.  Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. , 2019, Cancer cell.

[87]  T. Coroller,et al.  Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging , 2019, Clinical Cancer Research.

[88]  F. Bahrami,et al.  An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. , 2017, Mathematical biosciences.

[89]  Bo Wang,et al.  Visualization and analysis of single-cell RNA-seq data by kernel-based similarity learning , 2016, Nature Methods.

[90]  Shridar Ganesan,et al.  Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum. , 2018, JCO precision oncology.

[91]  Bernhard O. Palsson,et al.  The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models , 2013, BMC Systems Biology.

[92]  Bin Huang,et al.  RACIPE: a computational tool for modeling gene regulatory circuits using randomization , 2017, bioRxiv.

[93]  Margaret P. Chapman,et al.  Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer , 2018, Nature Communications.

[94]  Carlos L Arteaga,et al.  Cdk Inhibitor p27Kip1 and Hormone Dependence in Breast Cancer , 2004, Clinical Cancer Research.

[95]  Rui Zhao,et al.  Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients , 2018, PLoS Comput. Biol..

[96]  A Forsman,et al.  Rethinking phenotypic plasticity and its consequences for individuals, populations and species , 2014, Heredity.

[97]  L Biganzoli,et al.  Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[98]  Timothy Daley,et al.  Applications of species accumulation curves in large-scale biological data analysis , 2015, Quantitative Biology.

[99]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.